The GPR35 agonist lodoxamide has been shown to inhibit hepatic lipid accumulation, indicating its potential as a therapeutic agent for nonalcoholic fatty liver disease (NAFLD) (25). The gene discussed is GPR35; the disease is metabolic dysfunction-associated steatotic liver disease.